12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Synflorix: Phase III data

The double-blind, Finish Phase III FinIP trial in 47,369 children ages <19 months showed that there were no culture-confirmed vaccine-type cases of invasive pneumococcal disease detected in children receiving a 3+1 dosing schedule of Synflorix and 1 case in children receiving a 2+1 dosing schedule of Synflorix vs. 12 cases in children...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >